Mesoblast Advances Cellular Medicines Amid FDA Hopes

TipRanks10-19

Mesoblast (MESO) has released an update. Mesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476734919?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2","is_english":true,"pubTime":"2024-10-19 18:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476734919","market":"us","top_or_hot":-1,"title":"Mesoblast Advances Cellular Medicines Amid FDA Hopes","media":"TipRanks","content":"<div>\n<p>Mesoblast (MESO) has released an update.\nMesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mesoblast-advances-cellular-medicines-amid-103005991.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Advances Cellular Medicines Amid FDA Hopes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Advances Cellular Medicines Amid FDA Hopes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-19 18:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mesoblast-advances-cellular-medicines-amid-103005991.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (MESO) has released an update.\nMesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mesoblast-advances-cellular-medicines-amid-103005991.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCO","symbol_name":"麦迪逊医药","start_time":0,"source_url":"https://finance.yahoo.com/news/mesoblast-advances-cellular-medicines-amid-103005991.html","article_id":"2476734919","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mesoblast-advances-cellular-medicines-amid-103005991.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2476734919","pubTimestamp":1729333805,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Mesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company is preparing to launch Ryoncil, a treatment for steroid-refractory acute GvHD in children, pending FDA approval, and has secured $50 million to support commercialization efforts. Additionally, Mesoblast is progressing with a Phase 3 trial for rexlemestrocel-L to address chronic low back pain, highlighting its potential to enhance shareholder value through strategic partnerships and financial discipline.For further insights into MESO stock, check out TipRanks’ Stock Analysis page.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCO":"麦迪逊医药","BK4139":"生物科技","MESO":"Mesoblast Limited"},"translate_title":"Mesoblast在FDA的希望下推进细胞药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1,"MESO":1},"content_text":"Mesoblast (MESO) has released an update.\nMesoblast Limited is making strides in advancing its late-stage pipeline of innovative cellular medicines targeting serious inflammatory diseases. The company is preparing to launch Ryoncil®, a treatment for steroid-refractory acute GvHD in children, pending FDA approval, and has secured $50 million to support commercialization efforts. Additionally, Mesoblast is progressing with a Phase 3 trial for rexlemestrocel-L to address chronic low back pain, highlighting its potential to enhance shareholder value through strategic partnerships and financial discipline.\nFor further insights into MESO stock, check out TipRanks’ Stock Analysis page.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476734919"}